Recro Pharma Inc is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that develops non-opioid products for the treatment of acute pain. The company operates two divisions Acute Care division and a contract development and manufacturing or CDMO division. The Acute Care division is engaged in developing products for hospital and related settings. Its lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. The CDMO division develops and manufactures pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. The majority of the company's revenue is generated from its CDMO segment.